Medicis Receives FDA Clearance For Liposonix, But Doesn’t Plan to Launch
Medicis, the pharmaceutical company behind Restylane, Perlane and Dysport, recently announced FDA approval for Liposonix.
Liposonix is a new treatment that uses high-intensity, focused ultrasound to eliminate fat that is just beneath the skin. The company reportedly received FDA approval for “non-invasive waist circumference reduction.”
Medicis doesn’t plan to launch the treatment in the United States. In a press release issued this morning, the company stated:
Medicis is not planning to launch the LIPOSONIX system in the U.S., and would anticipate that plans for a U.S. launch will be announced by an acquiring company, if any, if and when such acquiring company deems appropriate.
The treatment is available in Canada, Japan and Europe. Although the procedure is officially cleared for sale in the U.S., people interested in it may need to wait until another company acquires the rights to market Liposonix technology from Medicis.
Medicis is best known for providing high quality injectable products, including Restylane and Perlane, some of the world’s most popular wrinkle fillers; and Dysport, the injectable botulinum toxin medication that works in a similar manner to Botox Cosmetic.Back to blog